---
title: "ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | TLX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288327814.md"
description: "ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | TLX Stock News"
datetime: "2026-06-01T13:00:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288327814.md)
  - [en](https://longbridge.com/en/news/288327814.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288327814.md)
---

# ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | TLX Stock News

ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 | TLX Stock News

### Related Stocks

- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)
- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)

## Related News & Research

- [ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News](https://longbridge.com/en/news/288311834.md)
- [BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 | ONC Stock News](https://longbridge.com/en/news/288251196.md)
- [Grail reports results from NHS-Galleri trial in presentation at ASCO meeting](https://longbridge.com/en/news/288210425.md)
- [15:15 ETVaniam Group and Women Leaders in Oncology Honor 2026 Young Investigator Award Recipients at ASCO](https://longbridge.com/en/news/288317167.md)
- [Does ADPT’s clonoSEQ Spotlight at ASCO and EHA Reveal a Durable MRD Moat in Oncology?](https://longbridge.com/en/news/288283687.md)